skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
Refinado por: Nome da Publicação: Atherosclerosis remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia
Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia

Laurens F Reeskamp John J. P Kastelein; Patrick M Moriarty; P. Barton Duell; Alberico L Catapano; Raul Dias dos Santos Filho; Christie M Ballantyne

Atherosclerosis v. 280, p. 109-117, 2019

Clare 2019

Acesso online. A biblioteca também possui exemplares impressos.

2
Comparative effects of cholesteryl ester transfer protein inhibition, statin and ezetimibe therapy on atherogenic and protective lipid factors: The accentuate trial
Comparative effects of cholesteryl ester transfer protein inhibition, statin and ezetimibe therapy on atherogenic and protective lipid factors: The accentuate trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Comparative effects of cholesteryl ester transfer protein inhibition, statin and ezetimibe therapy on atherogenic and protective lipid factors: The accentuate trial

Nicholls, S ; Ray, K ; Ballantyne, C ; Beacham, L ; Miller, D ; Ruotolo, G ; Riesmeyer, J

Atherosclerosis, 2016-09, Vol.252, p.e237-e238 [Periódico revisado por pares]

Elsevier B.V

Texto completo disponível

Citações Citado por
3
Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study
Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study

Hoogeveen, Ron C. ; Morrison, Alanna ; Boerwinkle, Eric ; Miles, J. Shawn ; Rhodes, Charles E. ; Sharrett, A. Richey ; Ballantyne, Christie M.

Atherosclerosis, 2005-12, Vol.183 (2), p.301-307 [Periódico revisado por pares]

Amsterdam: Elsevier Ireland Ltd

Texto completo disponível

Citações Citado por
4
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study

Ballantyne, Christie M ; Hoogeveen, Ron C ; Raya, Joe L ; Cain, Valerie A ; Palmer, Mike K ; Karlson, Björn W

Atherosclerosis, 2014-01, Vol.232 (1), p.86-93 [Periódico revisado por pares]

Ireland: Elsevier Ireland Ltd

Texto completo disponível

Citações Citado por
5
Bococizumab (rn316/pf-04950615), a monoclonal antibody against pcsk9 in statin-treated hypercholesterolemic subjects: Results from a randomized, placebo-controlled, dose-ranging study (nct: 01592240)
Bococizumab (rn316/pf-04950615), a monoclonal antibody against pcsk9 in statin-treated hypercholesterolemic subjects: Results from a randomized, placebo-controlled, dose-ranging study (nct: 01592240)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Bococizumab (rn316/pf-04950615), a monoclonal antibody against pcsk9 in statin-treated hypercholesterolemic subjects: Results from a randomized, placebo-controlled, dose-ranging study (nct: 01592240)

Ballantyne, C ; Neutel, J ; Cropp, A ; Duggan, W ; Wang, E ; Plowchalk, D ; Sweeney, K ; Kaila, N ; Vincent, J ; Bays, H

Atherosclerosis, 2014-08, Vol.235 (2), p.e75-e76 [Periódico revisado por pares]

Elsevier Ireland Ltd

Texto completo disponível

Citações Citado por
6
Correlation of serum triglyceride and its reduction by ω-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins
Correlation of serum triglyceride and its reduction by ω-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins
Material Type:
Artigo 		Adicionar ao Meu Espaço

Correlation of serum triglyceride and its reduction by ω-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins

Pownall, Henry J ; Brauchi, Danièle ; Kilinç, Cumhur ; Osmundsen, Karin ; Pao, Quein ; Payton-Ross, Charlotte ; Gotto, Antonio M ; Ballantyne, Christie M

Atherosclerosis, 1999-04, Vol.143 (2), p.285-297 [Periódico revisado por pares]

Amsterdam: Elsevier Ireland Ltd

Texto completo disponível

Citações Citado por
7
Small Dense Ldl-Cholesterol (Sdldl-C) As A Risk Enhancer Of Atherosclerotic Cardiovascular Disease (Ascvd): The Atherosclerosis Risk In Communities (Aric) Study
Small Dense Ldl-Cholesterol (Sdldl-C) As A Risk Enhancer Of Atherosclerotic Cardiovascular Disease (Ascvd): The Atherosclerosis Risk In Communities (Aric) Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Small Dense Ldl-Cholesterol (Sdldl-C) As A Risk Enhancer Of Atherosclerotic Cardiovascular Disease (Ascvd): The Atherosclerosis Risk In Communities (Aric) Study

Hoogeveen, R. ; Sun, W. ; Ballantyne, C.

Atherosclerosis, 2019-08, Vol.287, p.e277-e278 [Periódico revisado por pares]

Elsevier B.V

Texto completo disponível

Citações Citado por
8
Efficacy and safety of the oral PCSK9 macrocyclic peptide inhibitor MK-0616: A phase 2B randomized controlled trial
Efficacy and safety of the oral PCSK9 macrocyclic peptide inhibitor MK-0616: A phase 2B randomized controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and safety of the oral PCSK9 macrocyclic peptide inhibitor MK-0616: A phase 2B randomized controlled trial

Ballantyne, C. ; Banka, P. ; Mendez, G. ; Garcia, R. ; Rosenstock, J. ; Rodgers, A. ; Mendizabal, G. ; Mitchel, Y. ; Catapano, A.

Atherosclerosis, 2023-08, Vol.379, p.S21 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
ARO-ANG3, an investigational RNAI therapeutic, decreases serum LDL-cholesterol, apolipoprotein B, and angiopoietin-like protein 3 in patients with homozygous familial hypercholesterolaemia
ARO-ANG3, an investigational RNAI therapeutic, decreases serum LDL-cholesterol, apolipoprotein B, and angiopoietin-like protein 3 in patients with homozygous familial hypercholesterolaemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

ARO-ANG3, an investigational RNAI therapeutic, decreases serum LDL-cholesterol, apolipoprotein B, and angiopoietin-like protein 3 in patients with homozygous familial hypercholesterolaemia

Raal, F. ; Bergeron, J. ; Watts, G. ; Gaudet, D. ; Sullivan, D. ; Turner, T. ; Hegele, R. ; Ballantyne, C. ; Knowles, J. ; Goldberg, I. ; Fu, R. ; Alagarsamy, S. ; Hamilton, J. ; Rosenson, R.

Atherosclerosis, 2023-08, Vol.379, p.S43-S44 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
10
Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events: Lipoproteins and Coronary Atherosclerosis Study
Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events: Lipoproteins and Coronary Atherosclerosis Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events: Lipoproteins and Coronary Atherosclerosis Study

Sing, Karandeep ; Ballantyne, Christie M ; Ferlic, Laura ; Brugada, Ramon ; Cushman, Ian ; Dunn, J.Kay ; Herd, J.Alan ; Pownall, Henry J ; Gotto, Antonio M ; Marian, Ali J

Atherosclerosis, 1999-06, Vol.144 (2), p.435-442 [Periódico revisado por pares]

Amsterdam: Elsevier Ireland Ltd

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.